Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Indiana University
How would you approach a patient with grade 1/2 pancreatic neuroendocrine tumor after progressing on octreotide?
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
Answer from: Medical Oncologist at Community Practice
Tem/cape -- responses are good for pancreatic NET. PRRT Is great but so expensive. I’m finding it so hard to get.
Sign in or Register to read more
6227
Related Questions
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
How do you approach pelvic radiation therapy for a patient with multiple myeloma who needs more intensive therapy (e.g., Dara-KRd or impending CAR-T) with a risk of cytopenias?
What is the best treatment approach to a patient with HGBCL with FISH translocation of BCL-6 and c-Myc given new classification of this entity?
How would you approach unexpected chemo breaks during planned neoadjuvant chemoradiation for esophageal adenocarcinoma?
How would you approach treatment of a patient with adenocarcinoma of unknown primary only found in a left supraclavicular lymph node?
How (and when) is primary refractory AL amyloidosis defined following D-CyBorD treatment? Is there a threshold of biomarker reduction following 1-2 cycles that, if not met, should prompt early consideration of treatment change?
Would you consider adding encorafenib + cetuximab to adjuvant mFOLFOX for a patient with oligometastatic colon cancer with BRAF V600E mutation s/p metastasectomy and primary resection given the new data from the BREAKWATER trial?
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?